January 21, 2021
The leukemia expert talks about how current findings may hold promise for a larger group of patients in the future.
January 14, 2021
IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.
December 30, 2020
The leukemia expert discussed the clinical implications of findings demonstrating improved response for patients with acute myeloid leukemia with IDH mutations.
December 24, 2020
Dan Pollyea, MD discusses the response rate and overall survival of venetoclax for patients with acute myeloid leukemia with IDH mutations.
December 17, 2020
Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations